NEW HAVEN — The National Cancer Institute (NCI) has named Yale Cancer Center a lead site in a new clinical trials research network dedicated to improving treatment for the more than 1.6 million Americans diagnosed with cancer each year. The new system, called the National Clinical Trials Network (NCTN), is a consortium of 30 academic cancer centers.
“Clinical trials are the primary way advances in cancer treatment are made for cancer patients. Yale Cancer Center is gratified to join the NCTN since collaborating with other leading cancer centers will help us all deliver breakthroughs more quickly,” said Howard Hochster, MD, professor of medical oncology and associate director for clinical sciences at Yale Cancer Center. “We’re committed to bringing the best clinical and translational science from Yale to the group and using these collaborations to help lead the next generation of clinical trials to the national stage.”
One hundred clinical trials for multiple types of cancer are available to patients of Smilow Cancer Hospital and affiliated care centers. The growing portfolio of trials includes Phase I trials, which are the critical first step in testing new cancer drugs in patients.